Neu­roster­ix emerges with $63M to fol­low Karuna, Cerev­el

Small Swiss biotech Ad­dex Ther­a­peu­tics is trans­fer­ring its neu­ro­science as­sets and its al­losteric mod­u­la­tor plat­form to a new biotech that has picked up $63 mil­lion in a Se­ries A raise.

The 22-year-old pub­licly trad­ed Ad­dex will own about 20% of the new com­pa­ny called Neu­roster­ix, CEO Tim Dy­er said in an in­ter­view with End­points News ahead of the Wednes­day an­nounce­ment.

Dy­er will lead both com­pa­nies, and Neu­roster­ix will take Ad­dex’s fa­cil­i­ty and team of 19 em­ploy­ees with it, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER